Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled time : 06:03 save search
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Published: 2021-03-09 (Crawled : 06:03) - globenewswire.com
NVS | $93.43 0.93% 220K
|
Health Technology
|
| O: 0.14%
H: 0.76%
C: -0.37%
treatment lung cancer therapy cancer ev
FDA grants Breakthrough Device Designation for Roche's Elecsys Growth Differentiation Factor-15 (GDF-15) assay to help identify patients suitable for innovative treatment addressing unintentional weight loss in cancer patients
Published: 2021-02-08 (Crawled : 06:03) - globenewswire.com
PFE A | $25.44 0.2% 4.4M
|
Health Technology
|
| O: 0.11%
H: 0.15%
C: -0.4%
weight loss cancer treatment fda growth device designation
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
AGBA | News | $1.37 242.5% 76M
|
Finance
EGOX | $0.0835 131.94% 160M
|
ZCMD | $2.18 50.35% 24M
|
Commercial Services
RWOD | $12.0 50.06% 3.9M
|
n/a
CHRO | $1.73 41.22% 46K
|
n/a
NVFY | $2.77 31.28% 2.2M
|
Consumer Durables
AULT | $0.3174 31.1% 28M
|
Manufacturing
WISA 4 | $7.11 20.71% 4.7M
|
Electronic Technology
LIFW | News | $0.99 19.26% 800K
|
Administrative and Support and ...
PRTG | $0.285 18.75% 140K
|
Mining, Quarrying, and Oil and ...
Your saved searches
Save your searches and get alerts when important news are released.